Research-use information only. This page summarises published laboratory findings on SLU-PP-332. Material supplied by Peptides Lab UK is for laboratory research use only, not for human or veterinary use, and nothing here is medical or dosing advice.
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), studied as an “exercise mimetic” because it activates the same transcriptional programme that endurance exercise switches on in skeletal muscle. Unlike most compounds in a peptide catalogue, it is not a peptide at all — it is a small molecule — and its interest lies in reproducing the metabolic signature of exercise without the mechanical activity.
What SLU-PP-332 is
SLU-PP-332 is a synthetic pan-ERR agonist developed in academic research. The estrogen-related receptors are orphan nuclear receptors — structurally related to estrogen receptors but not activated by estrogen — that act as master regulators of oxidative metabolism and mitochondrial biogenesis. ERRα in particular is a central node in the transcriptional network controlling energy expenditure in muscle.
How SLU-PP-332 is described to work
Endurance exercise increases oxidative capacity in muscle largely through the PGC-1α/ERR transcriptional axis. SLU-PP-332 activates ERR directly, and the research literature reports that it:
- Upregulates genes associated with mitochondrial biogenesis and fatty acid oxidation
- Increases the proportion of oxidative (type I) muscle fibre characteristics in preclinical models
- Raises energy expenditure and fat oxidation without a corresponding increase in food intake in animal studies
The “exercise mimetic” framing comes from this reproduction of the endurance-training transcriptional signature. It is a research description of a mechanism, not a claim of equivalence to exercise.
Research context and honesty about the evidence
SLU-PP-332 is a relatively new research compound. The evidence base is preclinical — rodent and cell models — and there is little to no controlled human data. Its metabolic effects are of interest precisely because the ERR axis is well validated, but claims that extend animal findings to human outcomes are not supported by the current literature. Any research design should treat the human translation as an open question.
How SLU-PP-332 relates to other metabolic research compounds
SLU-PP-332 sits alongside other compounds studied for metabolic and body-composition endpoints but works through a distinct mechanism — nuclear receptor transcription rather than incretin signalling or growth-hormone axis stimulation. It is sometimes studied in parallel with 5-amino-1MQ (an NNMT inhibitor) and AOD-9604, though the three act on entirely separate pathways.
Dosage and handling as described in the literature
As a small molecule rather than a peptide, SLU-PP-332 is handled differently from the peptide catalogue — solubility and reconstitution follow small-molecule conventions, and the relevant solvent depends on the supplied form. Published protocols describe milligram-per-kilogram dosing in animal models; these describe research documentation only and are not instructions for human use. Confirm the appropriate diluent for the specific preparation rather than assuming bacteriostatic water.
The UK regulatory position
SLU-PP-332 is not a licensed medicine in the UK and is not approved for human consumption. Peptides Lab UK supplies it for laboratory research only, correctly labelled. Because it is a newer compound where identity and purity verification matter, insist on batch-specific analytical data; our quality-standards SOP sets out the testing applied to every batch.
Frequently asked questions
What is SLU-PP-332?
A synthetic small-molecule agonist of the estrogen-related receptors (ERRα/β/γ), studied as an exercise mimetic because it activates the transcriptional programme endurance exercise induces in muscle.
Is SLU-PP-332 a peptide?
No. It is a small molecule, not a peptide, despite appearing in research-peptide catalogues. Handling follows small-molecule conventions.
How does SLU-PP-332 work?
It directly activates estrogen-related receptors, master regulators of oxidative metabolism, upregulating mitochondrial biogenesis and fatty acid oxidation genes and increasing energy expenditure in preclinical models.
Is there human data on SLU-PP-332?
Little to none. The evidence base is preclinical. Extending animal findings to human outcomes is not currently supported.
Why is SLU-PP-332 called an exercise mimetic?
Because it reproduces the transcriptional signature endurance training induces in muscle. This describes a mechanism, not equivalence to exercise.
Is SLU-PP-332 legal in the UK?
It is not a licensed medicine in the UK. Supply for laboratory research, correctly labelled, is a separate lawful category.
Disclaimer: this content is for educational and research purposes only. SLU-PP-332 supplied by Peptides Lab UK is not intended for human or veterinary use.
